Potential Safety Concerns With Lixisenatide Despite Showing Slowed Motor Disability Progression in Phase 2 Trial for Early Parkinson Disease

The data is not yet there to proceed to prescribing,” Michael S. Okun, MD, national medical advisor for the Parkinson’s Foundation, told NeurologyLive®. “More importantly, the weight loss associated with GLP-1’s is not desirable in the majority of cases of Parkinson disease and the nausea and vomiting will not be a welcome symptom. The drug and trial is a step in the right direction, though there is much work to do.”

Top Clinical Takeaways

  • Lixisenatide demonstrated potential in slowing Parkinson disease progression over a year but raised concerns because of gastrointestinal adverse effects.
  • Researchers emphasize the need for longer and larger trials to fully understand the effects and safety profile of lixisenatide in patients with Parkinson disease.
  • While the trial results offer promise, longer exposure and evaluation in different stages of Parkinson disease are necessary to ascertain the drug’s efficacy and safety comprehensively.

Read the full article here!